Search Results For:

				GHIAA2019\MapguideSearch Object
(
    [search_parameters] => Array
        (
            [qs] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement
        )

    [filters] => Array
        (
            [text_search] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement
        )

    [child_filters] => Array
        (
        )

    [agreement_args] => 
    [provision_args] => Array
        (
            [post_type] => provision_document
            [posts_per_page] => -1
            [post__in] => Array
                (
                    [0] => 12976
                    [1] => 12944
                    [2] => 12943
                    [3] => 12941
                    [4] => 12975
                    [5] => 12974
                    [6] => 12973
                    [7] => 12967
                    [8] => 12968
                    [9] => 12966
                    [10] => 12965
                    [11] => 12964
                    [12] => 12962
                    [13] => 12961
                    [14] => 12960
                    [15] => 12958
                    [16] => 12957
                    [17] => 12956
                    [18] => 12948
                    [19] => 12942
                    [20] => 12945
                    [21] => 12947
                    [22] => 12946
                    [23] => 8484
                    [24] => 8469
                    [25] => 8468
                    [26] => 8467
                    [27] => 3757
                    [28] => 3756
                    [29] => 3755
                    [30] => 3754
                    [31] => 3753
                    [32] => 3751
                    [33] => 3749
                    [34] => 3748
                    [35] => 3747
                    [36] => 3746
                    [37] => 3744
                    [38] => 3743
                    [39] => 3726
                    [40] => 3725
                    [41] => 3724
                    [42] => 3722
                    [43] => 12976
                    [44] => 12944
                    [45] => 12943
                    [46] => 12941
                    [47] => 12975
                    [48] => 12974
                    [49] => 12973
                    [50] => 12967
                    [51] => 12968
                    [52] => 12966
                    [53] => 12965
                    [54] => 12964
                    [55] => 12962
                    [56] => 12961
                    [57] => 12960
                    [58] => 12958
                    [59] => 12957
                    [60] => 12956
                    [61] => 12948
                    [62] => 12942
                    [63] => 12945
                    [64] => 12947
                    [65] => 12946
                    [66] => 3744
                    [67] => 3743
                    [68] => 3722
                    [69] => 12870
                    [70] => 12765
                    [71] => 12774
                    [72] => 12770
                    [73] => 12769
                    [74] => 12768
                    [75] => 12767
                    [76] => 12766
                    [77] => 12764
                    [78] => 12762
                    [79] => 12761
                    [80] => 12760
                    [81] => 12759
                    [82] => 12758
                    [83] => 12757
                    [84] => 12756
                    [85] => 12755
                    [86] => 12772
                    [87] => 12771
                )

        )

    [text_agreement_args] => Array
        (
            [post_type] => agreement
            [posts_per_page] => -1
            [s] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement
        )

    [text_provision_args] => Array
        (
            [post_type] => provision_document
            [posts_per_page] => -1
            [s] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement
        )

    [agreement_ids] => Array
        (
        )

    [agreement_q_rslts] => 
    [provision_q_rslts] => 
    [text_agreement_q_rslts] => WP_Query Object
        (
            [query] => Array
                (
                    [post_type] => agreement
                    [posts_per_page] => -1
                    [s] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement
                )

            [query_vars] => Array
                (
                    [post_type] => agreement
                    [posts_per_page] => -1
                    [s] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement
                    [error] => 
                    [m] => 
                    [p] => 0
                    [post_parent] => 
                    [subpost] => 
                    [subpost_id] => 
                    [attachment] => 
                    [attachment_id] => 0
                    [name] => 
                    [pagename] => 
                    [page_id] => 0
                    [second] => 
                    [minute] => 
                    [hour] => 
                    [day] => 0
                    [monthnum] => 0
                    [year] => 0
                    [w] => 0
                    [category_name] => 
                    [tag] => 
                    [cat] => 
                    [tag_id] => 
                    [author] => 
                    [author_name] => 
                    [feed] => 
                    [tb] => 
                    [paged] => 0
                    [meta_key] => 
                    [meta_value] => 
                    [preview] => 
                    [sentence] => 
                    [title] => 
                    [fields] => all
                    [menu_order] => 
                    [embed] => 
                    [category__in] => Array
                        (
                        )

                    [category__not_in] => Array
                        (
                        )

                    [category__and] => Array
                        (
                        )

                    [post__in] => Array
                        (
                        )

                    [post__not_in] => Array
                        (
                        )

                    [post_name__in] => Array
                        (
                        )

                    [tag__in] => Array
                        (
                        )

                    [tag__not_in] => Array
                        (
                        )

                    [tag__and] => Array
                        (
                        )

                    [tag_slug__in] => Array
                        (
                        )

                    [tag_slug__and] => Array
                        (
                        )

                    [post_parent__in] => Array
                        (
                        )

                    [post_parent__not_in] => Array
                        (
                        )

                    [author__in] => Array
                        (
                        )

                    [author__not_in] => Array
                        (
                        )

                    [search_columns] => Array
                        (
                        )

                    [orderby] => title
                    [order] => ASC
                    [suppress_filters] => 
                    [ignore_sticky_posts] => 
                    [cache_results] => 1
                    [update_post_term_cache] => 1
                    [update_menu_item_cache] => 
                    [lazy_load_term_meta] => 1
                    [update_post_meta_cache] => 1
                    [nopaging] => 1
                    [comments_per_page] => 50
                    [no_found_rows] => 
                    [search_terms_count] => 7
                    [search_terms] => Array
                        (
                            [0] => CEPI
                            [1] => Valneva
                            [2] => Chikungunya
                            [3] => Vaccine
                            [4] => Funding
                            [5] => Agreement
                        )

                    [search_orderby_title] => Array
                        (
                            [0] => wpry_posts.post_title LIKE '{15d87fa296463e9923ff57272c66c7c79236f321e4e81e3e129416d59eed0c68}CEPI{15d87fa296463e9923ff57272c66c7c79236f321e4e81e3e129416d59eed0c68}'
                            [1] => wpry_posts.post_title LIKE '{15d87fa296463e9923ff57272c66c7c79236f321e4e81e3e129416d59eed0c68}Valneva{15d87fa296463e9923ff57272c66c7c79236f321e4e81e3e129416d59eed0c68}'
                            [2] => wpry_posts.post_title LIKE '{15d87fa296463e9923ff57272c66c7c79236f321e4e81e3e129416d59eed0c68}Chikungunya{15d87fa296463e9923ff57272c66c7c79236f321e4e81e3e129416d59eed0c68}'
                            [3] => wpry_posts.post_title LIKE '{15d87fa296463e9923ff57272c66c7c79236f321e4e81e3e129416d59eed0c68}Vaccine{15d87fa296463e9923ff57272c66c7c79236f321e4e81e3e129416d59eed0c68}'
                            [4] => wpry_posts.post_title LIKE '{15d87fa296463e9923ff57272c66c7c79236f321e4e81e3e129416d59eed0c68}Funding{15d87fa296463e9923ff57272c66c7c79236f321e4e81e3e129416d59eed0c68}'
                            [5] => wpry_posts.post_title LIKE '{15d87fa296463e9923ff57272c66c7c79236f321e4e81e3e129416d59eed0c68}Agreement{15d87fa296463e9923ff57272c66c7c79236f321e4e81e3e129416d59eed0c68}'
                        )

                )

            [tax_query] => WP_Tax_Query Object
                (
                    [queries] => Array
                        (
                        )

                    [relation] => AND
                    [table_aliases:protected] => Array
                        (
                        )

                    [queried_terms] => Array
                        (
                        )

                    [primary_table] => wpry_posts
                    [primary_id_column] => ID
                )

            [meta_query] => WP_Meta_Query Object
                (
                    [queries] => Array
                        (
                        )

                    [relation] => 
                    [meta_table] => 
                    [meta_id_column] => 
                    [primary_table] => 
                    [primary_id_column] => 
                    [table_aliases:protected] => Array
                        (
                        )

                    [clauses:protected] => Array
                        (
                        )

                    [has_or_relation:protected] => 
                )

            [date_query] => 
            [request] => SELECT  DISTINCT wpry_posts.*
					 FROM wpry_posts  INNER JOIN wpry_postmeta AS a ON ( a.post_id = wpry_posts.ID ) LEFT JOIN wpry_postmeta AS b ON ( (( b.post_id = a.post_id )) AND (( b.meta_key LIKE CONCAT( '\_', a.meta_key ) )) ) LEFT JOIN wpry_posts AS c ON ( ( c.post_name = b.meta_value ) AND ( c.post_type = 'acf-field' ) AND (( c.post_content LIKE '%:"text"%' ) OR ( c.post_content LIKE '%:"textarea"%' ) OR ( c.post_content LIKE '%:"wysiwyg"%' ) OR ( c.post_content LIKE '%:"checkbox"%' )) ) 
					 WHERE 1=1  AND ( ( ( b.meta_id IS NOT NULL ) AND ( c.ID IS NOT NULL ) AND ( a.meta_value LIKE '%CEPI%' ) AND ( a.meta_value LIKE '%-%' ) AND ( a.meta_value LIKE '%Valneva,%' ) AND ( a.meta_value LIKE '%Chikungunya%' ) AND ( a.meta_value LIKE '%Vaccine%' ) AND ( a.meta_value LIKE '%Funding%' ) AND ( a.meta_value LIKE '%Agreement%' ) ) OR ( ( ( wpry_posts.post_title LIKE '%CEPI%' ) OR ( wpry_posts.post_excerpt LIKE '%CEPI%' ) OR ( wpry_posts.post_content LIKE '%CEPI%' ) ) AND ( ( wpry_posts.post_title LIKE '%-%' ) OR ( wpry_posts.post_excerpt LIKE '%-%' ) OR ( wpry_posts.post_content LIKE '%-%' ) ) AND ( ( wpry_posts.post_title LIKE '%Valneva,%' ) OR ( wpry_posts.post_excerpt LIKE '%Valneva,%' ) OR ( wpry_posts.post_content LIKE '%Valneva,%' ) ) AND ( ( wpry_posts.post_title LIKE '%Chikungunya%' ) OR ( wpry_posts.post_excerpt LIKE '%Chikungunya%' ) OR ( wpry_posts.post_content LIKE '%Chikungunya%' ) ) AND ( ( wpry_posts.post_title LIKE '%Vaccine%' ) OR ( wpry_posts.post_excerpt LIKE '%Vaccine%' ) OR ( wpry_posts.post_content LIKE '%Vaccine%' ) ) AND ( ( wpry_posts.post_title LIKE '%Funding%' ) OR ( wpry_posts.post_excerpt LIKE '%Funding%' ) OR ( wpry_posts.post_content LIKE '%Funding%' ) ) AND ( ( wpry_posts.post_title LIKE '%Agreement%' ) OR ( wpry_posts.post_excerpt LIKE '%Agreement%' ) OR ( wpry_posts.post_content LIKE '%Agreement%' ) ) ) )  AND ((wpry_posts.post_type = 'agreement' AND (wpry_posts.post_status = 'publish' OR wpry_posts.post_status = 'acf-disabled')))
					 
					 ORDER BY wpry_posts.post_title ASC
					 
            [posts] => Array
                (
                    [0] => WP_Post Object
                        (
                            [ID] => 3719
                            [post_author] => 5
                            [post_date] => 2021-08-23 11:02:40
                            [post_date_gmt] => 2021-08-23 11:02:40
                            [post_content] => 
                            [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-09-15 11:58:51
                            [post_modified_gmt] => 2021-09-15 11:58:51
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=3719
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [1] => WP_Post Object
                        (
                            [ID] => 12939
                            [post_author] => 5
                            [post_date] => 2025-08-18 08:18:21
                            [post_date_gmt] => 2025-08-18 08:18:21
                            [post_content] => 
                            [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement 2
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2025-08-18 08:18:32
                            [post_modified_gmt] => 2025-08-18 08:18:32
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=12939
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                )

            [post_count] => 2
            [current_post] => -1
            [before_loop] => 1
            [in_the_loop] => 
            [post] => WP_Post Object
                (
                    [ID] => 3719
                    [post_author] => 5
                    [post_date] => 2021-08-23 11:02:40
                    [post_date_gmt] => 2021-08-23 11:02:40
                    [post_content] => 
                    [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-09-15 11:58:51
                    [post_modified_gmt] => 2021-09-15 11:58:51
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=agreement&p=3719
                    [menu_order] => 0
                    [post_type] => agreement
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [comment_count] => 0
            [current_comment] => -1
            [found_posts] => 2
            [max_num_pages] => 0
            [max_num_comment_pages] => 0
            [is_single] => 
            [is_preview] => 
            [is_page] => 
            [is_archive] => 1
            [is_date] => 
            [is_year] => 
            [is_month] => 
            [is_day] => 
            [is_time] => 
            [is_author] => 
            [is_category] => 
            [is_tag] => 
            [is_tax] => 
            [is_search] => 1
            [is_feed] => 
            [is_comment_feed] => 
            [is_trackback] => 
            [is_home] => 
            [is_privacy_policy] => 
            [is_404] => 
            [is_embed] => 
            [is_paged] => 
            [is_admin] => 
            [is_attachment] => 
            [is_singular] => 
            [is_robots] => 
            [is_favicon] => 
            [is_posts_page] => 
            [is_post_type_archive] => 1
            [query_vars_hash:WP_Query:private] => b46450eff58dcbc18ff75474c117c820
            [query_vars_changed:WP_Query:private] => 1
            [thumbnails_cached] => 
            [allow_query_attachment_by_filename:protected] => 
            [stopwords:WP_Query:private] => Array
                (
                    [0] => about
                    [1] => an
                    [2] => are
                    [3] => as
                    [4] => at
                    [5] => be
                    [6] => by
                    [7] => com
                    [8] => for
                    [9] => from
                    [10] => how
                    [11] => in
                    [12] => is
                    [13] => it
                    [14] => of
                    [15] => on
                    [16] => or
                    [17] => that
                    [18] => the
                    [19] => this
                    [20] => to
                    [21] => was
                    [22] => what
                    [23] => when
                    [24] => where
                    [25] => who
                    [26] => will
                    [27] => with
                    [28] => www
                )

            [compat_fields:WP_Query:private] => Array
                (
                    [0] => query_vars_hash
                    [1] => query_vars_changed
                )

            [compat_methods:WP_Query:private] => Array
                (
                    [0] => init_query_flags
                    [1] => parse_tax_query
                )

            [query_cache_key:WP_Query:private] => wp_query:3c2da97014c5d4e8de2030cb39de1b83
        )

    [text_provision_q_rslts] => WP_Query Object
        (
            [query] => Array
                (
                    [post_type] => provision_document
                    [posts_per_page] => -1
                    [s] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement
                )

            [query_vars] => Array
                (
                    [post_type] => provision_document
                    [posts_per_page] => -1
                    [s] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement
                    [error] => 
                    [m] => 
                    [p] => 0
                    [post_parent] => 
                    [subpost] => 
                    [subpost_id] => 
                    [attachment] => 
                    [attachment_id] => 0
                    [name] => 
                    [pagename] => 
                    [page_id] => 0
                    [second] => 
                    [minute] => 
                    [hour] => 
                    [day] => 0
                    [monthnum] => 0
                    [year] => 0
                    [w] => 0
                    [category_name] => 
                    [tag] => 
                    [cat] => 
                    [tag_id] => 
                    [author] => 
                    [author_name] => 
                    [feed] => 
                    [tb] => 
                    [paged] => 0
                    [meta_key] => 
                    [meta_value] => 
                    [preview] => 
                    [sentence] => 
                    [title] => 
                    [fields] => all
                    [menu_order] => 
                    [embed] => 
                    [category__in] => Array
                        (
                        )

                    [category__not_in] => Array
                        (
                        )

                    [category__and] => Array
                        (
                        )

                    [post__in] => Array
                        (
                        )

                    [post__not_in] => Array
                        (
                        )

                    [post_name__in] => Array
                        (
                        )

                    [tag__in] => Array
                        (
                        )

                    [tag__not_in] => Array
                        (
                        )

                    [tag__and] => Array
                        (
                        )

                    [tag_slug__in] => Array
                        (
                        )

                    [tag_slug__and] => Array
                        (
                        )

                    [post_parent__in] => Array
                        (
                        )

                    [post_parent__not_in] => Array
                        (
                        )

                    [author__in] => Array
                        (
                        )

                    [author__not_in] => Array
                        (
                        )

                    [search_columns] => Array
                        (
                        )

                    [suppress_filters] => 
                    [ignore_sticky_posts] => 
                    [cache_results] => 1
                    [update_post_term_cache] => 1
                    [update_menu_item_cache] => 
                    [lazy_load_term_meta] => 1
                    [update_post_meta_cache] => 1
                    [nopaging] => 1
                    [comments_per_page] => 50
                    [no_found_rows] => 
                    [search_terms_count] => 7
                    [search_terms] => Array
                        (
                            [0] => CEPI
                            [1] => Valneva
                            [2] => Chikungunya
                            [3] => Vaccine
                            [4] => Funding
                            [5] => Agreement
                        )

                    [search_orderby_title] => Array
                        (
                            [0] => wpry_posts.post_title LIKE '{15d87fa296463e9923ff57272c66c7c79236f321e4e81e3e129416d59eed0c68}CEPI{15d87fa296463e9923ff57272c66c7c79236f321e4e81e3e129416d59eed0c68}'
                            [1] => wpry_posts.post_title LIKE '{15d87fa296463e9923ff57272c66c7c79236f321e4e81e3e129416d59eed0c68}Valneva{15d87fa296463e9923ff57272c66c7c79236f321e4e81e3e129416d59eed0c68}'
                            [2] => wpry_posts.post_title LIKE '{15d87fa296463e9923ff57272c66c7c79236f321e4e81e3e129416d59eed0c68}Chikungunya{15d87fa296463e9923ff57272c66c7c79236f321e4e81e3e129416d59eed0c68}'
                            [3] => wpry_posts.post_title LIKE '{15d87fa296463e9923ff57272c66c7c79236f321e4e81e3e129416d59eed0c68}Vaccine{15d87fa296463e9923ff57272c66c7c79236f321e4e81e3e129416d59eed0c68}'
                            [4] => wpry_posts.post_title LIKE '{15d87fa296463e9923ff57272c66c7c79236f321e4e81e3e129416d59eed0c68}Funding{15d87fa296463e9923ff57272c66c7c79236f321e4e81e3e129416d59eed0c68}'
                            [5] => wpry_posts.post_title LIKE '{15d87fa296463e9923ff57272c66c7c79236f321e4e81e3e129416d59eed0c68}Agreement{15d87fa296463e9923ff57272c66c7c79236f321e4e81e3e129416d59eed0c68}'
                        )

                    [order] => DESC
                )

            [tax_query] => WP_Tax_Query Object
                (
                    [queries] => Array
                        (
                        )

                    [relation] => AND
                    [table_aliases:protected] => Array
                        (
                        )

                    [queried_terms] => Array
                        (
                        )

                    [primary_table] => wpry_posts
                    [primary_id_column] => ID
                )

            [meta_query] => WP_Meta_Query Object
                (
                    [queries] => Array
                        (
                        )

                    [relation] => 
                    [meta_table] => 
                    [meta_id_column] => 
                    [primary_table] => 
                    [primary_id_column] => 
                    [table_aliases:protected] => Array
                        (
                        )

                    [clauses:protected] => Array
                        (
                        )

                    [has_or_relation:protected] => 
                )

            [date_query] => 
            [request] => SELECT  DISTINCT wpry_posts.*
					 FROM wpry_posts  INNER JOIN wpry_postmeta AS a ON ( a.post_id = wpry_posts.ID ) LEFT JOIN wpry_postmeta AS b ON ( (( b.post_id = a.post_id )) AND (( b.meta_key LIKE CONCAT( '\_', a.meta_key ) )) ) LEFT JOIN wpry_posts AS c ON ( ( c.post_name = b.meta_value ) AND ( c.post_type = 'acf-field' ) AND (( c.post_content LIKE '%:"text"%' ) OR ( c.post_content LIKE '%:"textarea"%' ) OR ( c.post_content LIKE '%:"wysiwyg"%' ) OR ( c.post_content LIKE '%:"checkbox"%' )) ) 
					 WHERE 1=1  AND ( ( ( b.meta_id IS NOT NULL ) AND ( c.ID IS NOT NULL ) AND ( a.meta_value LIKE '%CEPI%' ) AND ( a.meta_value LIKE '%-%' ) AND ( a.meta_value LIKE '%Valneva,%' ) AND ( a.meta_value LIKE '%Chikungunya%' ) AND ( a.meta_value LIKE '%Vaccine%' ) AND ( a.meta_value LIKE '%Funding%' ) AND ( a.meta_value LIKE '%Agreement%' ) ) OR ( ( ( wpry_posts.post_title LIKE '%CEPI%' ) OR ( wpry_posts.post_excerpt LIKE '%CEPI%' ) OR ( wpry_posts.post_content LIKE '%CEPI%' ) ) AND ( ( wpry_posts.post_title LIKE '%-%' ) OR ( wpry_posts.post_excerpt LIKE '%-%' ) OR ( wpry_posts.post_content LIKE '%-%' ) ) AND ( ( wpry_posts.post_title LIKE '%Valneva,%' ) OR ( wpry_posts.post_excerpt LIKE '%Valneva,%' ) OR ( wpry_posts.post_content LIKE '%Valneva,%' ) ) AND ( ( wpry_posts.post_title LIKE '%Chikungunya%' ) OR ( wpry_posts.post_excerpt LIKE '%Chikungunya%' ) OR ( wpry_posts.post_content LIKE '%Chikungunya%' ) ) AND ( ( wpry_posts.post_title LIKE '%Vaccine%' ) OR ( wpry_posts.post_excerpt LIKE '%Vaccine%' ) OR ( wpry_posts.post_content LIKE '%Vaccine%' ) ) AND ( ( wpry_posts.post_title LIKE '%Funding%' ) OR ( wpry_posts.post_excerpt LIKE '%Funding%' ) OR ( wpry_posts.post_content LIKE '%Funding%' ) ) AND ( ( wpry_posts.post_title LIKE '%Agreement%' ) OR ( wpry_posts.post_excerpt LIKE '%Agreement%' ) OR ( wpry_posts.post_content LIKE '%Agreement%' ) ) ) )  AND ((wpry_posts.post_type = 'provision_document' AND (wpry_posts.post_status = 'publish' OR wpry_posts.post_status = 'acf-disabled')))
					 
					 ORDER BY (CASE WHEN wpry_posts.post_title LIKE '{15d87fa296463e9923ff57272c66c7c79236f321e4e81e3e129416d59eed0c68}CEPI{15d87fa296463e9923ff57272c66c7c79236f321e4e81e3e129416d59eed0c68}' AND wpry_posts.post_title LIKE '{15d87fa296463e9923ff57272c66c7c79236f321e4e81e3e129416d59eed0c68}Valneva{15d87fa296463e9923ff57272c66c7c79236f321e4e81e3e129416d59eed0c68}' AND wpry_posts.post_title LIKE '{15d87fa296463e9923ff57272c66c7c79236f321e4e81e3e129416d59eed0c68}Chikungunya{15d87fa296463e9923ff57272c66c7c79236f321e4e81e3e129416d59eed0c68}' AND wpry_posts.post_title LIKE '{15d87fa296463e9923ff57272c66c7c79236f321e4e81e3e129416d59eed0c68}Vaccine{15d87fa296463e9923ff57272c66c7c79236f321e4e81e3e129416d59eed0c68}' AND wpry_posts.post_title LIKE '{15d87fa296463e9923ff57272c66c7c79236f321e4e81e3e129416d59eed0c68}Funding{15d87fa296463e9923ff57272c66c7c79236f321e4e81e3e129416d59eed0c68}' AND wpry_posts.post_title LIKE '{15d87fa296463e9923ff57272c66c7c79236f321e4e81e3e129416d59eed0c68}Agreement{15d87fa296463e9923ff57272c66c7c79236f321e4e81e3e129416d59eed0c68}' THEN 2 WHEN wpry_posts.post_title LIKE '{15d87fa296463e9923ff57272c66c7c79236f321e4e81e3e129416d59eed0c68}CEPI{15d87fa296463e9923ff57272c66c7c79236f321e4e81e3e129416d59eed0c68}' OR wpry_posts.post_title LIKE '{15d87fa296463e9923ff57272c66c7c79236f321e4e81e3e129416d59eed0c68}Valneva{15d87fa296463e9923ff57272c66c7c79236f321e4e81e3e129416d59eed0c68}' OR wpry_posts.post_title LIKE '{15d87fa296463e9923ff57272c66c7c79236f321e4e81e3e129416d59eed0c68}Chikungunya{15d87fa296463e9923ff57272c66c7c79236f321e4e81e3e129416d59eed0c68}' OR wpry_posts.post_title LIKE '{15d87fa296463e9923ff57272c66c7c79236f321e4e81e3e129416d59eed0c68}Vaccine{15d87fa296463e9923ff57272c66c7c79236f321e4e81e3e129416d59eed0c68}' OR wpry_posts.post_title LIKE '{15d87fa296463e9923ff57272c66c7c79236f321e4e81e3e129416d59eed0c68}Funding{15d87fa296463e9923ff57272c66c7c79236f321e4e81e3e129416d59eed0c68}' OR wpry_posts.post_title LIKE '{15d87fa296463e9923ff57272c66c7c79236f321e4e81e3e129416d59eed0c68}Agreement{15d87fa296463e9923ff57272c66c7c79236f321e4e81e3e129416d59eed0c68}' THEN 3 ELSE 6 END), wpry_posts.post_date DESC
					 
            [posts] => Array
                (
                    [0] => WP_Post Object
                        (
                            [ID] => 12976
                            [post_author] => 5
                            [post_date] => 2025-09-01 12:40:41
                            [post_date_gmt] => 2025-09-01 12:40:41
                            [post_content] => 
                            [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement 2
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2-24
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2025-09-01 12:40:41
                            [post_modified_gmt] => 2025-09-01 12:40:41
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12976
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [1] => WP_Post Object
                        (
                            [ID] => 12944
                            [post_author] => 5
                            [post_date] => 2025-08-18 11:30:39
                            [post_date_gmt] => 2025-08-18 11:30:39
                            [post_content] => 
                            [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement 2
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2-23
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2025-08-18 11:32:31
                            [post_modified_gmt] => 2025-08-18 11:32:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12944
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [2] => WP_Post Object
                        (
                            [ID] => 12943
                            [post_author] => 5
                            [post_date] => 2025-08-18 11:30:34
                            [post_date_gmt] => 2025-08-18 11:30:34
                            [post_content] => 
                            [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement 2
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2-22
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2025-08-18 11:35:22
                            [post_modified_gmt] => 2025-08-18 11:35:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12943
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [3] => WP_Post Object
                        (
                            [ID] => 12941
                            [post_author] => 5
                            [post_date] => 2025-08-18 11:30:25
                            [post_date_gmt] => 2025-08-18 11:30:25
                            [post_content] => 
                            [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement 2
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2-21
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2025-08-18 11:33:46
                            [post_modified_gmt] => 2025-08-18 11:33:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12941
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [4] => WP_Post Object
                        (
                            [ID] => 12975
                            [post_author] => 5
                            [post_date] => 2025-08-18 07:52:18
                            [post_date_gmt] => 2025-08-18 07:52:18
                            [post_content] => 
                            [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement 2
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2-20
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2025-08-18 07:52:18
                            [post_modified_gmt] => 2025-08-18 07:52:18
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12975
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [5] => WP_Post Object
                        (
                            [ID] => 12974
                            [post_author] => 5
                            [post_date] => 2025-08-18 07:45:02
                            [post_date_gmt] => 2025-08-18 07:45:02
                            [post_content] => 
                            [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement 2
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2-19
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2025-08-18 11:30:01
                            [post_modified_gmt] => 2025-08-18 11:30:01
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12974
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [6] => WP_Post Object
                        (
                            [ID] => 12973
                            [post_author] => 5
                            [post_date] => 2025-08-18 07:30:44
                            [post_date_gmt] => 2025-08-18 07:30:44
                            [post_content] => 
                            [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement 2
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2-18
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2025-08-18 07:30:44
                            [post_modified_gmt] => 2025-08-18 07:30:44
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12973
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [7] => WP_Post Object
                        (
                            [ID] => 12967
                            [post_author] => 5
                            [post_date] => 2025-08-13 15:17:58
                            [post_date_gmt] => 2025-08-13 15:17:58
                            [post_content] => 
                            [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement 2
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2-17
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2025-08-18 07:19:34
                            [post_modified_gmt] => 2025-08-18 07:19:34
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12967
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [8] => WP_Post Object
                        (
                            [ID] => 12968
                            [post_author] => 5
                            [post_date] => 2025-08-13 15:11:08
                            [post_date_gmt] => 2025-08-13 15:11:08
                            [post_content] => 
                            [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement 2
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2-16
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2025-08-13 15:11:08
                            [post_modified_gmt] => 2025-08-13 15:11:08
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12968
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [9] => WP_Post Object
                        (
                            [ID] => 12966
                            [post_author] => 5
                            [post_date] => 2025-08-13 14:57:13
                            [post_date_gmt] => 2025-08-13 14:57:13
                            [post_content] => 
                            [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement 2
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2025-08-13 14:57:13
                            [post_modified_gmt] => 2025-08-13 14:57:13
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12966
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [10] => WP_Post Object
                        (
                            [ID] => 12965
                            [post_author] => 5
                            [post_date] => 2025-08-13 13:03:33
                            [post_date_gmt] => 2025-08-13 13:03:33
                            [post_content] => 
                            [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement 2
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2025-08-18 08:45:54
                            [post_modified_gmt] => 2025-08-18 08:45:54
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12965
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [11] => WP_Post Object
                        (
                            [ID] => 12964
                            [post_author] => 5
                            [post_date] => 2025-08-13 12:25:57
                            [post_date_gmt] => 2025-08-13 12:25:57
                            [post_content] => 
                            [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement 2
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2025-08-13 12:30:46
                            [post_modified_gmt] => 2025-08-13 12:30:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12964
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [12] => WP_Post Object
                        (
                            [ID] => 12962
                            [post_author] => 5
                            [post_date] => 2025-08-13 11:42:16
                            [post_date_gmt] => 2025-08-13 11:42:16
                            [post_content] => 
                            [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement 2
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2025-08-20 08:43:11
                            [post_modified_gmt] => 2025-08-20 08:43:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12962
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [13] => WP_Post Object
                        (
                            [ID] => 12961
                            [post_author] => 5
                            [post_date] => 2025-08-12 15:33:02
                            [post_date_gmt] => 2025-08-12 15:33:02
                            [post_content] => 
                            [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement 2
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2025-08-18 11:23:50
                            [post_modified_gmt] => 2025-08-18 11:23:50
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12961
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [14] => WP_Post Object
                        (
                            [ID] => 12960
                            [post_author] => 5
                            [post_date] => 2025-08-12 14:04:59
                            [post_date_gmt] => 2025-08-12 14:04:59
                            [post_content] => 
                            [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement 2
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2025-08-12 14:04:59
                            [post_modified_gmt] => 2025-08-12 14:04:59
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12960
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [15] => WP_Post Object
                        (
                            [ID] => 12958
                            [post_author] => 5
                            [post_date] => 2025-08-12 09:01:55
                            [post_date_gmt] => 2025-08-12 09:01:55
                            [post_content] => 
                            [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement 2
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2025-08-13 12:28:25
                            [post_modified_gmt] => 2025-08-13 12:28:25
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12958
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [16] => WP_Post Object
                        (
                            [ID] => 12957
                            [post_author] => 5
                            [post_date] => 2025-08-12 07:59:21
                            [post_date_gmt] => 2025-08-12 07:59:21
                            [post_content] => 
                            [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement 2
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2025-08-12 07:59:21
                            [post_modified_gmt] => 2025-08-12 07:59:21
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12957
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [17] => WP_Post Object
                        (
                            [ID] => 12956
                            [post_author] => 5
                            [post_date] => 2025-08-11 15:13:11
                            [post_date_gmt] => 2025-08-11 15:13:11
                            [post_content] => 
                            [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement 2
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2025-08-11 15:13:11
                            [post_modified_gmt] => 2025-08-11 15:13:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12956
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [18] => WP_Post Object
                        (
                            [ID] => 12948
                            [post_author] => 5
                            [post_date] => 2025-08-11 14:59:51
                            [post_date_gmt] => 2025-08-11 14:59:51
                            [post_content] => 
                            [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement 2
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2025-08-20 08:45:26
                            [post_modified_gmt] => 2025-08-20 08:45:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12948
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [19] => WP_Post Object
                        (
                            [ID] => 12942
                            [post_author] => 5
                            [post_date] => 2025-08-07 09:50:44
                            [post_date_gmt] => 2025-08-07 09:50:44
                            [post_content] => 
                            [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement 2
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2025-08-20 08:27:19
                            [post_modified_gmt] => 2025-08-20 08:27:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12942
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [20] => WP_Post Object
                        (
                            [ID] => 12945
                            [post_author] => 5
                            [post_date] => 2025-08-07 09:50:01
                            [post_date_gmt] => 2025-08-07 09:50:01
                            [post_content] => 
                            [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement 2
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2025-08-18 08:26:12
                            [post_modified_gmt] => 2025-08-18 08:26:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12945
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [21] => WP_Post Object
                        (
                            [ID] => 12947
                            [post_author] => 5
                            [post_date] => 2025-08-07 09:49:53
                            [post_date_gmt] => 2025-08-07 09:49:53
                            [post_content] => 
                            [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement 2
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2025-08-20 08:48:35
                            [post_modified_gmt] => 2025-08-20 08:48:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12947
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [22] => WP_Post Object
                        (
                            [ID] => 12946
                            [post_author] => 5
                            [post_date] => 2025-08-07 08:51:52
                            [post_date_gmt] => 2025-08-07 08:51:52
                            [post_content] => 
                            [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement 2
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2025-08-12 15:12:39
                            [post_modified_gmt] => 2025-08-12 15:12:39
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12946
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [23] => WP_Post Object
                        (
                            [ID] => 3744
                            [post_author] => 5
                            [post_date] => 2021-08-24 10:32:54
                            [post_date_gmt] => 2021-08-24 10:32:54
                            [post_content] => 
                            [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-10 16:23:55
                            [post_modified_gmt] => 2024-01-10 16:23:55
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3744
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [24] => WP_Post Object
                        (
                            [ID] => 3743
                            [post_author] => 5
                            [post_date] => 2021-08-24 10:19:00
                            [post_date_gmt] => 2021-08-24 10:19:00
                            [post_content] => 
                            [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-10 16:25:37
                            [post_modified_gmt] => 2024-01-10 16:25:37
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3743
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [25] => WP_Post Object
                        (
                            [ID] => 3722
                            [post_author] => 5
                            [post_date] => 2021-08-23 12:12:50
                            [post_date_gmt] => 2021-08-23 12:12:50
                            [post_content] => 
                            [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-26 12:24:33
                            [post_modified_gmt] => 2023-06-26 12:24:33
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3722
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [26] => WP_Post Object
                        (
                            [ID] => 12870
                            [post_author] => 5
                            [post_date] => 2025-07-24 06:23:29
                            [post_date_gmt] => 2025-07-24 06:23:29
                            [post_content] => 
                            [post_title] => Valneva - Serum Institute of India, Chikungunya Vaccine License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => valneva-serum-institute-of-india-chikungunya-vaccine-license-agreement-19
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2025-07-24 06:24:19
                            [post_modified_gmt] => 2025-07-24 06:24:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12870
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [27] => WP_Post Object
                        (
                            [ID] => 12765
                            [post_author] => 5
                            [post_date] => 2025-07-23 13:21:13
                            [post_date_gmt] => 2025-07-23 13:21:13
                            [post_content] => 
                            [post_title] => Valneva - Serum Institute of India, Chikungunya Vaccine License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => valneva-serum-institute-of-india-chikungunya-vaccine-license-agreement-18
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2025-07-23 13:21:13
                            [post_modified_gmt] => 2025-07-23 13:21:13
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12765
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [28] => WP_Post Object
                        (
                            [ID] => 12774
                            [post_author] => 5
                            [post_date] => 2025-06-13 15:04:58
                            [post_date_gmt] => 2025-06-13 15:04:58
                            [post_content] => 
                            [post_title] => Valneva - Serum Institute of India, Chikungunya Vaccine License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => valneva-serum-institute-of-india-chikungunya-vaccine-license-agreement-17
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2025-06-13 15:04:58
                            [post_modified_gmt] => 2025-06-13 15:04:58
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12774
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [29] => WP_Post Object
                        (
                            [ID] => 12770
                            [post_author] => 5
                            [post_date] => 2025-06-13 14:16:03
                            [post_date_gmt] => 2025-06-13 14:16:03
                            [post_content] => 
                            [post_title] => Valneva - Serum Institute of India, Chikungunya Vaccine License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => valneva-serum-institute-of-india-chikungunya-vaccine-license-agreement-16
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2025-06-13 14:46:37
                            [post_modified_gmt] => 2025-06-13 14:46:37
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12770
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [30] => WP_Post Object
                        (
                            [ID] => 12769
                            [post_author] => 5
                            [post_date] => 2025-06-13 14:15:58
                            [post_date_gmt] => 2025-06-13 14:15:58
                            [post_content] => 
                            [post_title] => Valneva - Serum Institute of India, Chikungunya Vaccine License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => valneva-serum-institute-of-india-chikungunya-vaccine-license-agreement-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2025-06-13 14:42:49
                            [post_modified_gmt] => 2025-06-13 14:42:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12769
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [31] => WP_Post Object
                        (
                            [ID] => 12768
                            [post_author] => 5
                            [post_date] => 2025-06-13 14:15:52
                            [post_date_gmt] => 2025-06-13 14:15:52
                            [post_content] => 
                            [post_title] => Valneva - Serum Institute of India, Chikungunya Vaccine License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => valneva-serum-institute-of-india-chikungunya-vaccine-license-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2025-06-13 14:15:52
                            [post_modified_gmt] => 2025-06-13 14:15:52
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12768
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [32] => WP_Post Object
                        (
                            [ID] => 12767
                            [post_author] => 5
                            [post_date] => 2025-06-13 14:15:45
                            [post_date_gmt] => 2025-06-13 14:15:45
                            [post_content] => 
                            [post_title] => Valneva - Serum Institute of India, Chikungunya Vaccine License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => valneva-serum-institute-of-india-chikungunya-vaccine-license-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2025-06-13 14:41:27
                            [post_modified_gmt] => 2025-06-13 14:41:27
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12767
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [33] => WP_Post Object
                        (
                            [ID] => 12766
                            [post_author] => 5
                            [post_date] => 2025-06-13 14:15:38
                            [post_date_gmt] => 2025-06-13 14:15:38
                            [post_content] => 
                            [post_title] => Valneva - Serum Institute of India, Chikungunya Vaccine License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => valneva-serum-institute-of-india-chikungunya-vaccine-license-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2025-06-13 14:15:38
                            [post_modified_gmt] => 2025-06-13 14:15:38
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12766
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [34] => WP_Post Object
                        (
                            [ID] => 12764
                            [post_author] => 5
                            [post_date] => 2025-06-13 14:15:31
                            [post_date_gmt] => 2025-06-13 14:15:31
                            [post_content] => 
                            [post_title] => Valneva - Serum Institute of India, Chikungunya Vaccine License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => valneva-serum-institute-of-india-chikungunya-vaccine-license-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2025-06-13 14:15:31
                            [post_modified_gmt] => 2025-06-13 14:15:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12764
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [35] => WP_Post Object
                        (
                            [ID] => 12762
                            [post_author] => 5
                            [post_date] => 2025-06-13 14:15:22
                            [post_date_gmt] => 2025-06-13 14:15:22
                            [post_content] => 
                            [post_title] => Valneva - Serum Institute of India, Chikungunya Vaccine License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => valneva-serum-institute-of-india-chikungunya-vaccine-license-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2025-06-13 14:15:22
                            [post_modified_gmt] => 2025-06-13 14:15:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12762
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [36] => WP_Post Object
                        (
                            [ID] => 12761
                            [post_author] => 5
                            [post_date] => 2025-06-13 14:15:18
                            [post_date_gmt] => 2025-06-13 14:15:18
                            [post_content] => 
                            [post_title] => Valneva - Serum Institute of India, Chikungunya Vaccine License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => valneva-serum-institute-of-india-chikungunya-vaccine-license-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2025-06-13 14:38:41
                            [post_modified_gmt] => 2025-06-13 14:38:41
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12761
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [37] => WP_Post Object
                        (
                            [ID] => 12760
                            [post_author] => 5
                            [post_date] => 2025-06-13 14:15:10
                            [post_date_gmt] => 2025-06-13 14:15:10
                            [post_content] => 
                            [post_title] => Valneva - Serum Institute of India, Chikungunya Vaccine License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => valneva-serum-institute-of-india-chikungunya-vaccine-license-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2025-06-13 14:33:06
                            [post_modified_gmt] => 2025-06-13 14:33:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12760
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [38] => WP_Post Object
                        (
                            [ID] => 12759
                            [post_author] => 5
                            [post_date] => 2025-06-13 14:15:03
                            [post_date_gmt] => 2025-06-13 14:15:03
                            [post_content] => 
                            [post_title] => Valneva - Serum Institute of India, Chikungunya Vaccine License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => valneva-serum-institute-of-india-chikungunya-vaccine-license-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2025-06-13 14:31:52
                            [post_modified_gmt] => 2025-06-13 14:31:52
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12759
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [39] => WP_Post Object
                        (
                            [ID] => 12758
                            [post_author] => 5
                            [post_date] => 2025-06-13 14:14:57
                            [post_date_gmt] => 2025-06-13 14:14:57
                            [post_content] => 
                            [post_title] => Valneva - Serum Institute of India, Chikungunya Vaccine License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => valneva-serum-institute-of-india-chikungunya-vaccine-license-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2025-06-13 14:14:57
                            [post_modified_gmt] => 2025-06-13 14:14:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12758
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [40] => WP_Post Object
                        (
                            [ID] => 12757
                            [post_author] => 5
                            [post_date] => 2025-06-13 14:14:51
                            [post_date_gmt] => 2025-06-13 14:14:51
                            [post_content] => 
                            [post_title] => Valneva - Serum Institute of India, Chikungunya Vaccine License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => valneva-serum-institute-of-india-chikungunya-vaccine-license-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2025-06-13 14:14:51
                            [post_modified_gmt] => 2025-06-13 14:14:51
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12757
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [41] => WP_Post Object
                        (
                            [ID] => 12756
                            [post_author] => 5
                            [post_date] => 2025-06-13 14:14:36
                            [post_date_gmt] => 2025-06-13 14:14:36
                            [post_content] => 
                            [post_title] => Valneva - Serum Institute of India, Chikungunya Vaccine License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => valneva-serum-institute-of-india-chikungunya-vaccine-license-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2025-06-13 14:40:06
                            [post_modified_gmt] => 2025-06-13 14:40:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12756
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [42] => WP_Post Object
                        (
                            [ID] => 12755
                            [post_author] => 5
                            [post_date] => 2025-06-13 14:14:30
                            [post_date_gmt] => 2025-06-13 14:14:30
                            [post_content] => 
                            [post_title] => Valneva - Serum Institute of India, Chikungunya Vaccine License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => valneva-serum-institute-of-india-chikungunya-vaccine-license-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2025-06-13 14:14:30
                            [post_modified_gmt] => 2025-06-13 14:14:30
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12755
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [43] => WP_Post Object
                        (
                            [ID] => 12772
                            [post_author] => 5
                            [post_date] => 2025-06-13 14:14:14
                            [post_date_gmt] => 2025-06-13 14:14:14
                            [post_content] => 
                            [post_title] => Valneva - Serum Institute of India, Chikungunya Vaccine License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => valneva-serum-institute-of-india-chikungunya-vaccine-license-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2025-06-13 14:45:54
                            [post_modified_gmt] => 2025-06-13 14:45:54
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12772
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [44] => WP_Post Object
                        (
                            [ID] => 12771
                            [post_author] => 5
                            [post_date] => 2025-06-13 13:43:26
                            [post_date_gmt] => 2025-06-13 13:43:26
                            [post_content] => 
                            [post_title] => Valneva - Serum Institute of India, Chikungunya Vaccine License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => valneva-serum-institute-of-india-chikungunya-vaccine-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2025-06-13 13:43:26
                            [post_modified_gmt] => 2025-06-13 13:43:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12771
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                )

            [post_count] => 45
            [current_post] => -1
            [before_loop] => 1
            [in_the_loop] => 
            [post] => WP_Post Object
                (
                    [ID] => 12976
                    [post_author] => 5
                    [post_date] => 2025-09-01 12:40:41
                    [post_date_gmt] => 2025-09-01 12:40:41
                    [post_content] => 
                    [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement 2
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2-24
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2025-09-01 12:40:41
                    [post_modified_gmt] => 2025-09-01 12:40:41
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12976
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [comment_count] => 0
            [current_comment] => -1
            [found_posts] => 45
            [max_num_pages] => 0
            [max_num_comment_pages] => 0
            [is_single] => 
            [is_preview] => 
            [is_page] => 
            [is_archive] => 1
            [is_date] => 
            [is_year] => 
            [is_month] => 
            [is_day] => 
            [is_time] => 
            [is_author] => 
            [is_category] => 
            [is_tag] => 
            [is_tax] => 
            [is_search] => 1
            [is_feed] => 
            [is_comment_feed] => 
            [is_trackback] => 
            [is_home] => 
            [is_privacy_policy] => 
            [is_404] => 
            [is_embed] => 
            [is_paged] => 
            [is_admin] => 
            [is_attachment] => 
            [is_singular] => 
            [is_robots] => 
            [is_favicon] => 
            [is_posts_page] => 
            [is_post_type_archive] => 1
            [query_vars_hash:WP_Query:private] => ec448d10df090da02ed99f9f53b3c3ae
            [query_vars_changed:WP_Query:private] => 1
            [thumbnails_cached] => 
            [allow_query_attachment_by_filename:protected] => 
            [stopwords:WP_Query:private] => Array
                (
                    [0] => about
                    [1] => an
                    [2] => are
                    [3] => as
                    [4] => at
                    [5] => be
                    [6] => by
                    [7] => com
                    [8] => for
                    [9] => from
                    [10] => how
                    [11] => in
                    [12] => is
                    [13] => it
                    [14] => of
                    [15] => on
                    [16] => or
                    [17] => that
                    [18] => the
                    [19] => this
                    [20] => to
                    [21] => was
                    [22] => what
                    [23] => when
                    [24] => where
                    [25] => who
                    [26] => will
                    [27] => with
                    [28] => www
                )

            [compat_fields:WP_Query:private] => Array
                (
                    [0] => query_vars_hash
                    [1] => query_vars_changed
                )

            [compat_methods:WP_Query:private] => Array
                (
                    [0] => init_query_flags
                    [1] => parse_tax_query
                )

            [query_cache_key:WP_Query:private] => wp_query:4d8841123371999f5d8c397d46c6cb5e
        )

    [provisions] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 12976
                    [post_author] => 5
                    [post_date] => 2025-09-01 12:40:41
                    [post_date_gmt] => 2025-09-01 12:40:41
                    [post_content] => 
                    [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement 2
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2-24
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2025-09-01 12:40:41
                    [post_modified_gmt] => 2025-09-01 12:40:41
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12976
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [1] => WP_Post Object
                (
                    [ID] => 12944
                    [post_author] => 5
                    [post_date] => 2025-08-18 11:30:39
                    [post_date_gmt] => 2025-08-18 11:30:39
                    [post_content] => 
                    [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement 2
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2-23
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2025-08-18 11:32:31
                    [post_modified_gmt] => 2025-08-18 11:32:31
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12944
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [2] => WP_Post Object
                (
                    [ID] => 12943
                    [post_author] => 5
                    [post_date] => 2025-08-18 11:30:34
                    [post_date_gmt] => 2025-08-18 11:30:34
                    [post_content] => 
                    [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement 2
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2-22
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2025-08-18 11:35:22
                    [post_modified_gmt] => 2025-08-18 11:35:22
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12943
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [3] => WP_Post Object
                (
                    [ID] => 12941
                    [post_author] => 5
                    [post_date] => 2025-08-18 11:30:25
                    [post_date_gmt] => 2025-08-18 11:30:25
                    [post_content] => 
                    [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement 2
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2-21
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2025-08-18 11:33:46
                    [post_modified_gmt] => 2025-08-18 11:33:46
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12941
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [4] => WP_Post Object
                (
                    [ID] => 12975
                    [post_author] => 5
                    [post_date] => 2025-08-18 07:52:18
                    [post_date_gmt] => 2025-08-18 07:52:18
                    [post_content] => 
                    [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement 2
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2-20
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2025-08-18 07:52:18
                    [post_modified_gmt] => 2025-08-18 07:52:18
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12975
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [5] => WP_Post Object
                (
                    [ID] => 12974
                    [post_author] => 5
                    [post_date] => 2025-08-18 07:45:02
                    [post_date_gmt] => 2025-08-18 07:45:02
                    [post_content] => 
                    [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement 2
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2-19
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2025-08-18 11:30:01
                    [post_modified_gmt] => 2025-08-18 11:30:01
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12974
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [6] => WP_Post Object
                (
                    [ID] => 12973
                    [post_author] => 5
                    [post_date] => 2025-08-18 07:30:44
                    [post_date_gmt] => 2025-08-18 07:30:44
                    [post_content] => 
                    [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement 2
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2-18
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2025-08-18 07:30:44
                    [post_modified_gmt] => 2025-08-18 07:30:44
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12973
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [7] => WP_Post Object
                (
                    [ID] => 12967
                    [post_author] => 5
                    [post_date] => 2025-08-13 15:17:58
                    [post_date_gmt] => 2025-08-13 15:17:58
                    [post_content] => 
                    [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement 2
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2-17
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2025-08-18 07:19:34
                    [post_modified_gmt] => 2025-08-18 07:19:34
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12967
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [8] => WP_Post Object
                (
                    [ID] => 12968
                    [post_author] => 5
                    [post_date] => 2025-08-13 15:11:08
                    [post_date_gmt] => 2025-08-13 15:11:08
                    [post_content] => 
                    [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement 2
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2-16
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2025-08-13 15:11:08
                    [post_modified_gmt] => 2025-08-13 15:11:08
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12968
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [9] => WP_Post Object
                (
                    [ID] => 12966
                    [post_author] => 5
                    [post_date] => 2025-08-13 14:57:13
                    [post_date_gmt] => 2025-08-13 14:57:13
                    [post_content] => 
                    [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement 2
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2-15
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2025-08-13 14:57:13
                    [post_modified_gmt] => 2025-08-13 14:57:13
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12966
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [10] => WP_Post Object
                (
                    [ID] => 12965
                    [post_author] => 5
                    [post_date] => 2025-08-13 13:03:33
                    [post_date_gmt] => 2025-08-13 13:03:33
                    [post_content] => 
                    [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement 2
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2-14
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2025-08-18 08:45:54
                    [post_modified_gmt] => 2025-08-18 08:45:54
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12965
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [11] => WP_Post Object
                (
                    [ID] => 12964
                    [post_author] => 5
                    [post_date] => 2025-08-13 12:25:57
                    [post_date_gmt] => 2025-08-13 12:25:57
                    [post_content] => 
                    [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement 2
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2-13
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2025-08-13 12:30:46
                    [post_modified_gmt] => 2025-08-13 12:30:46
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12964
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [12] => WP_Post Object
                (
                    [ID] => 12962
                    [post_author] => 5
                    [post_date] => 2025-08-13 11:42:16
                    [post_date_gmt] => 2025-08-13 11:42:16
                    [post_content] => 
                    [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement 2
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2025-08-20 08:43:11
                    [post_modified_gmt] => 2025-08-20 08:43:11
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12962
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [13] => WP_Post Object
                (
                    [ID] => 12961
                    [post_author] => 5
                    [post_date] => 2025-08-12 15:33:02
                    [post_date_gmt] => 2025-08-12 15:33:02
                    [post_content] => 
                    [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement 2
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2025-08-18 11:23:50
                    [post_modified_gmt] => 2025-08-18 11:23:50
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12961
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [14] => WP_Post Object
                (
                    [ID] => 12960
                    [post_author] => 5
                    [post_date] => 2025-08-12 14:04:59
                    [post_date_gmt] => 2025-08-12 14:04:59
                    [post_content] => 
                    [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement 2
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2025-08-12 14:04:59
                    [post_modified_gmt] => 2025-08-12 14:04:59
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12960
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [15] => WP_Post Object
                (
                    [ID] => 12958
                    [post_author] => 5
                    [post_date] => 2025-08-12 09:01:55
                    [post_date_gmt] => 2025-08-12 09:01:55
                    [post_content] => 
                    [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement 2
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2025-08-13 12:28:25
                    [post_modified_gmt] => 2025-08-13 12:28:25
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12958
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [16] => WP_Post Object
                (
                    [ID] => 12957
                    [post_author] => 5
                    [post_date] => 2025-08-12 07:59:21
                    [post_date_gmt] => 2025-08-12 07:59:21
                    [post_content] => 
                    [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement 2
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2025-08-12 07:59:21
                    [post_modified_gmt] => 2025-08-12 07:59:21
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12957
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [17] => WP_Post Object
                (
                    [ID] => 12956
                    [post_author] => 5
                    [post_date] => 2025-08-11 15:13:11
                    [post_date_gmt] => 2025-08-11 15:13:11
                    [post_content] => 
                    [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement 2
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2025-08-11 15:13:11
                    [post_modified_gmt] => 2025-08-11 15:13:11
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12956
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [18] => WP_Post Object
                (
                    [ID] => 12948
                    [post_author] => 5
                    [post_date] => 2025-08-11 14:59:51
                    [post_date_gmt] => 2025-08-11 14:59:51
                    [post_content] => 
                    [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement 2
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2025-08-20 08:45:26
                    [post_modified_gmt] => 2025-08-20 08:45:26
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12948
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [19] => WP_Post Object
                (
                    [ID] => 12942
                    [post_author] => 5
                    [post_date] => 2025-08-07 09:50:44
                    [post_date_gmt] => 2025-08-07 09:50:44
                    [post_content] => 
                    [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement 2
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2025-08-20 08:27:19
                    [post_modified_gmt] => 2025-08-20 08:27:19
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12942
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [20] => WP_Post Object
                (
                    [ID] => 12945
                    [post_author] => 5
                    [post_date] => 2025-08-07 09:50:01
                    [post_date_gmt] => 2025-08-07 09:50:01
                    [post_content] => 
                    [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement 2
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2025-08-18 08:26:12
                    [post_modified_gmt] => 2025-08-18 08:26:12
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12945
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [21] => WP_Post Object
                (
                    [ID] => 12947
                    [post_author] => 5
                    [post_date] => 2025-08-07 09:49:53
                    [post_date_gmt] => 2025-08-07 09:49:53
                    [post_content] => 
                    [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement 2
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2025-08-20 08:48:35
                    [post_modified_gmt] => 2025-08-20 08:48:35
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12947
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [22] => WP_Post Object
                (
                    [ID] => 12946
                    [post_author] => 5
                    [post_date] => 2025-08-07 08:51:52
                    [post_date_gmt] => 2025-08-07 08:51:52
                    [post_content] => 
                    [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement 2
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2025-08-12 15:12:39
                    [post_modified_gmt] => 2025-08-12 15:12:39
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12946
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [23] => WP_Post Object
                (
                    [ID] => 12870
                    [post_author] => 5
                    [post_date] => 2025-07-24 06:23:29
                    [post_date_gmt] => 2025-07-24 06:23:29
                    [post_content] => 
                    [post_title] => Valneva - Serum Institute of India, Chikungunya Vaccine License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => valneva-serum-institute-of-india-chikungunya-vaccine-license-agreement-19
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2025-07-24 06:24:19
                    [post_modified_gmt] => 2025-07-24 06:24:19
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12870
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [24] => WP_Post Object
                (
                    [ID] => 12765
                    [post_author] => 5
                    [post_date] => 2025-07-23 13:21:13
                    [post_date_gmt] => 2025-07-23 13:21:13
                    [post_content] => 
                    [post_title] => Valneva - Serum Institute of India, Chikungunya Vaccine License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => valneva-serum-institute-of-india-chikungunya-vaccine-license-agreement-18
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2025-07-23 13:21:13
                    [post_modified_gmt] => 2025-07-23 13:21:13
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12765
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [25] => WP_Post Object
                (
                    [ID] => 12774
                    [post_author] => 5
                    [post_date] => 2025-06-13 15:04:58
                    [post_date_gmt] => 2025-06-13 15:04:58
                    [post_content] => 
                    [post_title] => Valneva - Serum Institute of India, Chikungunya Vaccine License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => valneva-serum-institute-of-india-chikungunya-vaccine-license-agreement-17
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2025-06-13 15:04:58
                    [post_modified_gmt] => 2025-06-13 15:04:58
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12774
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [26] => WP_Post Object
                (
                    [ID] => 12770
                    [post_author] => 5
                    [post_date] => 2025-06-13 14:16:03
                    [post_date_gmt] => 2025-06-13 14:16:03
                    [post_content] => 
                    [post_title] => Valneva - Serum Institute of India, Chikungunya Vaccine License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => valneva-serum-institute-of-india-chikungunya-vaccine-license-agreement-16
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2025-06-13 14:46:37
                    [post_modified_gmt] => 2025-06-13 14:46:37
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12770
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [27] => WP_Post Object
                (
                    [ID] => 12769
                    [post_author] => 5
                    [post_date] => 2025-06-13 14:15:58
                    [post_date_gmt] => 2025-06-13 14:15:58
                    [post_content] => 
                    [post_title] => Valneva - Serum Institute of India, Chikungunya Vaccine License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => valneva-serum-institute-of-india-chikungunya-vaccine-license-agreement-15
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2025-06-13 14:42:49
                    [post_modified_gmt] => 2025-06-13 14:42:49
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12769
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [28] => WP_Post Object
                (
                    [ID] => 12768
                    [post_author] => 5
                    [post_date] => 2025-06-13 14:15:52
                    [post_date_gmt] => 2025-06-13 14:15:52
                    [post_content] => 
                    [post_title] => Valneva - Serum Institute of India, Chikungunya Vaccine License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => valneva-serum-institute-of-india-chikungunya-vaccine-license-agreement-14
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2025-06-13 14:15:52
                    [post_modified_gmt] => 2025-06-13 14:15:52
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12768
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [29] => WP_Post Object
                (
                    [ID] => 12767
                    [post_author] => 5
                    [post_date] => 2025-06-13 14:15:45
                    [post_date_gmt] => 2025-06-13 14:15:45
                    [post_content] => 
                    [post_title] => Valneva - Serum Institute of India, Chikungunya Vaccine License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => valneva-serum-institute-of-india-chikungunya-vaccine-license-agreement-13
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2025-06-13 14:41:27
                    [post_modified_gmt] => 2025-06-13 14:41:27
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12767
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [30] => WP_Post Object
                (
                    [ID] => 12766
                    [post_author] => 5
                    [post_date] => 2025-06-13 14:15:38
                    [post_date_gmt] => 2025-06-13 14:15:38
                    [post_content] => 
                    [post_title] => Valneva - Serum Institute of India, Chikungunya Vaccine License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => valneva-serum-institute-of-india-chikungunya-vaccine-license-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2025-06-13 14:15:38
                    [post_modified_gmt] => 2025-06-13 14:15:38
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12766
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [31] => WP_Post Object
                (
                    [ID] => 12764
                    [post_author] => 5
                    [post_date] => 2025-06-13 14:15:31
                    [post_date_gmt] => 2025-06-13 14:15:31
                    [post_content] => 
                    [post_title] => Valneva - Serum Institute of India, Chikungunya Vaccine License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => valneva-serum-institute-of-india-chikungunya-vaccine-license-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2025-06-13 14:15:31
                    [post_modified_gmt] => 2025-06-13 14:15:31
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12764
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [32] => WP_Post Object
                (
                    [ID] => 12762
                    [post_author] => 5
                    [post_date] => 2025-06-13 14:15:22
                    [post_date_gmt] => 2025-06-13 14:15:22
                    [post_content] => 
                    [post_title] => Valneva - Serum Institute of India, Chikungunya Vaccine License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => valneva-serum-institute-of-india-chikungunya-vaccine-license-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2025-06-13 14:15:22
                    [post_modified_gmt] => 2025-06-13 14:15:22
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12762
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [33] => WP_Post Object
                (
                    [ID] => 12761
                    [post_author] => 5
                    [post_date] => 2025-06-13 14:15:18
                    [post_date_gmt] => 2025-06-13 14:15:18
                    [post_content] => 
                    [post_title] => Valneva - Serum Institute of India, Chikungunya Vaccine License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => valneva-serum-institute-of-india-chikungunya-vaccine-license-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2025-06-13 14:38:41
                    [post_modified_gmt] => 2025-06-13 14:38:41
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12761
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [34] => WP_Post Object
                (
                    [ID] => 12760
                    [post_author] => 5
                    [post_date] => 2025-06-13 14:15:10
                    [post_date_gmt] => 2025-06-13 14:15:10
                    [post_content] => 
                    [post_title] => Valneva - Serum Institute of India, Chikungunya Vaccine License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => valneva-serum-institute-of-india-chikungunya-vaccine-license-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2025-06-13 14:33:06
                    [post_modified_gmt] => 2025-06-13 14:33:06
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12760
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [35] => WP_Post Object
                (
                    [ID] => 12759
                    [post_author] => 5
                    [post_date] => 2025-06-13 14:15:03
                    [post_date_gmt] => 2025-06-13 14:15:03
                    [post_content] => 
                    [post_title] => Valneva - Serum Institute of India, Chikungunya Vaccine License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => valneva-serum-institute-of-india-chikungunya-vaccine-license-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2025-06-13 14:31:52
                    [post_modified_gmt] => 2025-06-13 14:31:52
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12759
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [36] => WP_Post Object
                (
                    [ID] => 12758
                    [post_author] => 5
                    [post_date] => 2025-06-13 14:14:57
                    [post_date_gmt] => 2025-06-13 14:14:57
                    [post_content] => 
                    [post_title] => Valneva - Serum Institute of India, Chikungunya Vaccine License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => valneva-serum-institute-of-india-chikungunya-vaccine-license-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2025-06-13 14:14:57
                    [post_modified_gmt] => 2025-06-13 14:14:57
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12758
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [37] => WP_Post Object
                (
                    [ID] => 12757
                    [post_author] => 5
                    [post_date] => 2025-06-13 14:14:51
                    [post_date_gmt] => 2025-06-13 14:14:51
                    [post_content] => 
                    [post_title] => Valneva - Serum Institute of India, Chikungunya Vaccine License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => valneva-serum-institute-of-india-chikungunya-vaccine-license-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2025-06-13 14:14:51
                    [post_modified_gmt] => 2025-06-13 14:14:51
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12757
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [38] => WP_Post Object
                (
                    [ID] => 12756
                    [post_author] => 5
                    [post_date] => 2025-06-13 14:14:36
                    [post_date_gmt] => 2025-06-13 14:14:36
                    [post_content] => 
                    [post_title] => Valneva - Serum Institute of India, Chikungunya Vaccine License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => valneva-serum-institute-of-india-chikungunya-vaccine-license-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2025-06-13 14:40:06
                    [post_modified_gmt] => 2025-06-13 14:40:06
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12756
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [39] => WP_Post Object
                (
                    [ID] => 12755
                    [post_author] => 5
                    [post_date] => 2025-06-13 14:14:30
                    [post_date_gmt] => 2025-06-13 14:14:30
                    [post_content] => 
                    [post_title] => Valneva - Serum Institute of India, Chikungunya Vaccine License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => valneva-serum-institute-of-india-chikungunya-vaccine-license-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2025-06-13 14:14:30
                    [post_modified_gmt] => 2025-06-13 14:14:30
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12755
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [40] => WP_Post Object
                (
                    [ID] => 12772
                    [post_author] => 5
                    [post_date] => 2025-06-13 14:14:14
                    [post_date_gmt] => 2025-06-13 14:14:14
                    [post_content] => 
                    [post_title] => Valneva - Serum Institute of India, Chikungunya Vaccine License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => valneva-serum-institute-of-india-chikungunya-vaccine-license-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2025-06-13 14:45:54
                    [post_modified_gmt] => 2025-06-13 14:45:54
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12772
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [41] => WP_Post Object
                (
                    [ID] => 12771
                    [post_author] => 5
                    [post_date] => 2025-06-13 13:43:26
                    [post_date_gmt] => 2025-06-13 13:43:26
                    [post_content] => 
                    [post_title] => Valneva - Serum Institute of India, Chikungunya Vaccine License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => valneva-serum-institute-of-india-chikungunya-vaccine-license-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2025-06-13 13:43:26
                    [post_modified_gmt] => 2025-06-13 13:43:26
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12771
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [42] => WP_Post Object
                (
                    [ID] => 8484
                    [post_author] => 5
                    [post_date] => 2023-01-19 09:17:50
                    [post_date_gmt] => 2023-01-19 09:17:50
                    [post_content] => 
                    [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-20
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-04 10:47:03
                    [post_modified_gmt] => 2024-09-04 10:47:03
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8484
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [43] => WP_Post Object
                (
                    [ID] => 8469
                    [post_author] => 5
                    [post_date] => 2023-01-13 13:35:47
                    [post_date_gmt] => 2023-01-13 13:35:47
                    [post_content] => 
                    [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-19
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-26 13:54:14
                    [post_modified_gmt] => 2023-06-26 13:54:14
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8469
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [44] => WP_Post Object
                (
                    [ID] => 8468
                    [post_author] => 5
                    [post_date] => 2023-01-11 14:35:38
                    [post_date_gmt] => 2023-01-11 14:35:38
                    [post_content] => 
                    [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-13
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-22 14:55:43
                    [post_modified_gmt] => 2023-06-22 14:55:43
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8468
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [45] => WP_Post Object
                (
                    [ID] => 8467
                    [post_author] => 5
                    [post_date] => 2023-01-11 14:29:13
                    [post_date_gmt] => 2023-01-11 14:29:13
                    [post_content] => 
                    [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-22 14:52:17
                    [post_modified_gmt] => 2023-06-22 14:52:17
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8467
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [46] => WP_Post Object
                (
                    [ID] => 3757
                    [post_author] => 5
                    [post_date] => 2021-08-25 08:42:34
                    [post_date_gmt] => 2021-08-25 08:42:34
                    [post_content] => 
                    [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-18
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-26 13:48:41
                    [post_modified_gmt] => 2023-06-26 13:48:41
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3757
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [47] => WP_Post Object
                (
                    [ID] => 3756
                    [post_author] => 5
                    [post_date] => 2021-08-25 08:10:37
                    [post_date_gmt] => 2021-08-25 08:10:37
                    [post_content] => 
                    [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-17
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-26 12:23:27
                    [post_modified_gmt] => 2023-06-26 12:23:27
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3756
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [48] => WP_Post Object
                (
                    [ID] => 3755
                    [post_author] => 5
                    [post_date] => 2021-08-25 07:55:51
                    [post_date_gmt] => 2021-08-25 07:55:51
                    [post_content] => 
                    [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-16
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-01-10 16:26:18
                    [post_modified_gmt] => 2024-01-10 16:26:18
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3755
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [49] => WP_Post Object
                (
                    [ID] => 3754
                    [post_author] => 5
                    [post_date] => 2021-08-24 13:43:37
                    [post_date_gmt] => 2021-08-24 13:43:37
                    [post_content] => 
                    [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-15
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-27 11:40:49
                    [post_modified_gmt] => 2023-06-27 11:40:49
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3754
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [50] => WP_Post Object
                (
                    [ID] => 3753
                    [post_author] => 5
                    [post_date] => 2021-08-24 13:14:41
                    [post_date_gmt] => 2021-08-24 13:14:41
                    [post_content] => 
                    [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-14
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-26 14:08:59
                    [post_modified_gmt] => 2023-06-26 14:08:59
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3753
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [51] => WP_Post Object
                (
                    [ID] => 3751
                    [post_author] => 5
                    [post_date] => 2021-08-24 12:54:56
                    [post_date_gmt] => 2021-08-24 12:54:56
                    [post_content] => 
                    [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-26 14:08:20
                    [post_modified_gmt] => 2023-06-26 14:08:20
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3751
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [52] => WP_Post Object
                (
                    [ID] => 3749
                    [post_author] => 5
                    [post_date] => 2021-08-24 12:40:53
                    [post_date_gmt] => 2021-08-24 12:40:53
                    [post_content] => 
                    [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-27 11:35:25
                    [post_modified_gmt] => 2023-06-27 11:35:25
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3749
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [53] => WP_Post Object
                (
                    [ID] => 3748
                    [post_author] => 5
                    [post_date] => 2021-08-24 12:31:07
                    [post_date_gmt] => 2021-08-24 12:31:07
                    [post_content] => 
                    [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-10-16 14:19:34
                    [post_modified_gmt] => 2023-10-16 14:19:34
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3748
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [54] => WP_Post Object
                (
                    [ID] => 3747
                    [post_author] => 5
                    [post_date] => 2021-08-24 11:12:07
                    [post_date_gmt] => 2021-08-24 11:12:07
                    [post_content] => 
                    [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-26 12:19:26
                    [post_modified_gmt] => 2023-06-26 12:19:26
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3747
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [55] => WP_Post Object
                (
                    [ID] => 3746
                    [post_author] => 5
                    [post_date] => 2021-08-24 10:45:05
                    [post_date_gmt] => 2021-08-24 10:45:05
                    [post_content] => 
                    [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-26 13:56:28
                    [post_modified_gmt] => 2023-06-26 13:56:28
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3746
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [56] => WP_Post Object
                (
                    [ID] => 3744
                    [post_author] => 5
                    [post_date] => 2021-08-24 10:32:54
                    [post_date_gmt] => 2021-08-24 10:32:54
                    [post_content] => 
                    [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-01-10 16:23:55
                    [post_modified_gmt] => 2024-01-10 16:23:55
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3744
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [57] => WP_Post Object
                (
                    [ID] => 3743
                    [post_author] => 5
                    [post_date] => 2021-08-24 10:19:00
                    [post_date_gmt] => 2021-08-24 10:19:00
                    [post_content] => 
                    [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-01-10 16:25:37
                    [post_modified_gmt] => 2024-01-10 16:25:37
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3743
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [58] => WP_Post Object
                (
                    [ID] => 3726
                    [post_author] => 5
                    [post_date] => 2021-08-23 16:13:39
                    [post_date_gmt] => 2021-08-23 16:13:39
                    [post_content] => 
                    [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2025-11-06 11:29:41
                    [post_modified_gmt] => 2025-11-06 11:29:41
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3726
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [59] => WP_Post Object
                (
                    [ID] => 3725
                    [post_author] => 5
                    [post_date] => 2021-08-23 13:56:41
                    [post_date_gmt] => 2021-08-23 13:56:41
                    [post_content] => 
                    [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-26 13:50:49
                    [post_modified_gmt] => 2023-06-26 13:50:49
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3725
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [60] => WP_Post Object
                (
                    [ID] => 3724
                    [post_author] => 5
                    [post_date] => 2021-08-23 13:11:07
                    [post_date_gmt] => 2021-08-23 13:11:07
                    [post_content] => 
                    [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2025-08-07 08:18:22
                    [post_modified_gmt] => 2025-08-07 08:18:22
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3724
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [61] => WP_Post Object
                (
                    [ID] => 3722
                    [post_author] => 5
                    [post_date] => 2021-08-23 12:12:50
                    [post_date_gmt] => 2021-08-23 12:12:50
                    [post_content] => 
                    [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-26 12:24:33
                    [post_modified_gmt] => 2023-06-26 12:24:33
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3722
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

        )

    [invalid_get] => 
    [is_text_search] => 1
    [has_agreement_filters] => 
    [has_any_agreement_filter] => Array
        (
        )

    [found_agreements] => 
    [has_provision_filters] => 
    [found_provisions] => 1
    [lbl_quick_search:GHIAA2019\MapguideSearch:private] => Search results for:
    [lbl_issue:GHIAA2019\MapguideSearch:private] => Issue:
    [lbl_key_term:GHIAA2019\MapguideSearch:private] => Key Term:
    [lbl_agreement_type:GHIAA2019\MapguideSearch:private] => Agreement Type:
    [lbl_partner_type:GHIAA2019\MapguideSearch:private] => Partner Type:
    [lbl_technology:GHIAA2019\MapguideSearch:private] => Technology:
    [lbl_development_stage:GHIAA2019\MapguideSearch:private] => Development Stage:
    [issues_by_id:GHIAA2019\MapguideSearch:private] => Array
        (
            [101] => WP_Term Object
                (
                    [term_id] => 101
                    [name] => Access plans & principles
                    [slug] => equitable-access
                    [term_group] => 0
                    [term_taxonomy_id] => 101
                    [taxonomy] => issue
                    [description] => 
 	How should equitable or global access be defined?
 	Should the developer be required to comply with an equitable access policy?
 	Should the developer be required to establish an access plan?

                    [parent] => 46
                    [count] => 64
                    [filter] => raw
                    [parent_name] => Equitable access
                    [parent_slug] => access-to-medicines
                )

            [100] => WP_Term Object
                (
                    [term_id] => 100
                    [name] => Affordable pricing
                    [slug] => pricing
                    [term_group] => 0
                    [term_taxonomy_id] => 100
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 57
                    [filter] => raw
                    [parent_name] => Equitable access
                    [parent_slug] => access-to-medicines
                )

            [66] => WP_Term Object
                (
                    [term_id] => 66
                    [name] => Benefit sharing
                    [slug] => benefit-revenue-sharing
                    [term_group] => 0
                    [term_taxonomy_id] => 66
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 19
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [53] => WP_Term Object
                (
                    [term_id] => 53
                    [name] => Business model
                    [slug] => business-model
                    [term_group] => 0
                    [term_taxonomy_id] => 53
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [371] => WP_Term Object
                (
                    [term_id] => 371
                    [name] => Clinical trial conduct
                    [slug] => clinical-trial-conduct
                    [term_group] => 0
                    [term_taxonomy_id] => 371
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 16
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [84] => WP_Term Object
                (
                    [term_id] => 84
                    [name] => Confidentiality
                    [slug] => confidentiality
                    [term_group] => 0
                    [term_taxonomy_id] => 84
                    [taxonomy] => issue
                    [description] => 
 	What is the scope of confidential information?
 	What are the obligations of the parties to protect confidential information?
 	Are there any exceptions to the confidentiality obligations?
 	Are the parties permitted to make public announcements related to the project?
 	Can the parties use each other’s name and logo for general marketing materials?

                    [parent] => 49
                    [count] => 123
                    [filter] => raw
                    [parent_name] => Protecting & sharing information
                    [parent_slug] => information-sharing
                )

            [271] => WP_Term Object
                (
                    [term_id] => 271
                    [name] => Donation
                    [slug] => donation
                    [term_group] => 0
                    [term_taxonomy_id] => 271
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 5
                    [filter] => raw
                    [parent_name] => Equitable access
                    [parent_slug] => access-to-medicines
                )

            [72] => WP_Term Object
                (
                    [term_id] => 72
                    [name] => Effects of termination
                    [slug] => effect-of-termination
                    [term_group] => 0
                    [term_taxonomy_id] => 72
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 52
                    [count] => 106
                    [filter] => raw
                    [parent_name] => Term & termination
                    [parent_slug] => term-and-termination
                )

            [281] => WP_Term Object
                (
                    [term_id] => 281
                    [name] => Ensuring continuity
                    [slug] => ensuring-continuity
                    [term_group] => 0
                    [term_taxonomy_id] => 281
                    [taxonomy] => issue
                    [description] => 
 	Under what circumstances can the continuity rights be exercised? (What are the conditions precedent?)
 	What is an appropriate scope for the continuity rights? What are the rights and obligations of each party?
 	Should related license grants vest upon execution of the agreement, or at a later stage in development?
 	Should there be an escrow requirement?
 	Should there be any restrictions on the developer’s ability to transfer project-related intellectual property to a third party?

                    [parent] => 46
                    [count] => 64
                    [filter] => raw
                    [parent_name] => Equitable access
                    [parent_slug] => access-to-medicines
                )

            [46] => WP_Term Object
                (
                    [term_id] => 46
                    [name] => Equitable access
                    [slug] => access-to-medicines
                    [term_group] => 0
                    [term_taxonomy_id] => 46
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [278] => WP_Term Object
                (
                    [term_id] => 278
                    [name] => Governance
                    [slug] => roles-responsibilities
                    [term_group] => 0
                    [term_taxonomy_id] => 278
                    [taxonomy] => issue
                    [description] => 
 	Do the parties govern the project through a joint steering committee ("JSC")? If so, what are the parties expressly designated roles and responsibilities with respect to the JSC?
 	Are there other committees, important governance bodies, or designated individual positions? What are the parties' roles and responsibilities with respect to them?
 	Are the parties required to meet in accordance with a defined schedule for decision-making and progress reporting activities?
 	What are the resolution mechanisms for disputes related to the agreement?
 	Are there any requirements for policies or procedures to manage potential conflicts of interest?

                    [parent] => 53
                    [count] => 109
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [80] => WP_Term Object
                (
                    [term_id] => 80
                    [name] => Indemnification & liability
                    [slug] => indemnity
                    [term_group] => 0
                    [term_taxonomy_id] => 80
                    [taxonomy] => issue
                    [description] => 
 	What occurrences could result in a liability claim against which one party will indemnify the other?
 	Are there any circumstances under which one party will not indemnify the other?
 	What is the process for managing liability claims?
 	Are there government or other types of indemnification schemes?
 	Is there any limitation or monetary cap on each party’s liabilities under the agreement?

                    [parent] => 50
                    [count] => 120
                    [filter] => raw
                    [parent_name] => Liability
                    [parent_slug] => liability
                )

            [257] => WP_Term Object
                (
                    [term_id] => 257
                    [name] => Information sharing
                    [slug] => information-sharing-information-sharing
                    [term_group] => 0
                    [term_taxonomy_id] => 257
                    [taxonomy] => issue
                    [description] => 
 	What financial and project progress information must be shared between the parties?
 	What is the required timeline for sharing information?
 	How is the receiving party permitted to use the information received?
 	Do the parties have the right to verify the information reported?

                    [parent] => 49
                    [count] => 114
                    [filter] => raw
                    [parent_name] => Protecting & sharing information
                    [parent_slug] => information-sharing
                )

            [109] => WP_Term Object
                (
                    [term_id] => 109
                    [name] => Insurance
                    [slug] => insurance
                    [term_group] => 0
                    [term_taxonomy_id] => 109
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 50
                    [count] => 76
                    [filter] => raw
                    [parent_name] => Liability
                    [parent_slug] => liability
                )

            [48] => WP_Term Object
                (
                    [term_id] => 48
                    [name] => Intellectual property
                    [slug] => ip-ownership
                    [term_group] => 0
                    [term_taxonomy_id] => 48
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [50] => WP_Term Object
                (
                    [term_id] => 50
                    [name] => Liability
                    [slug] => liability
                    [term_group] => 0
                    [term_taxonomy_id] => 50
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [88] => WP_Term Object
                (
                    [term_id] => 88
                    [name] => License grants
                    [slug] => license-grants
                    [term_group] => 0
                    [term_taxonomy_id] => 88
                    [taxonomy] => issue
                    [description] => 
 	Are any licenses granted for the use of background or foreground intellectual property?
 	What is the scope of the licensed intellectual property?
 	What is the territory of the license?
 	Is the license exclusive or non-exclusive?
 	Are there any restrictions on the use of the licensed intellectual property?
 	Are there any specific obligations to exploit the licensed intellectual property?
 	Can the licensee grant sublicenses to third parties?
 	Will products manufactured under license be marketed as branded or generic? (i.e. will they bear the licensor’s trademarks/trade dress)

                    [parent] => 48
                    [count] => 115
                    [filter] => raw
                    [parent_name] => Intellectual property
                    [parent_slug] => ip-ownership
                )

            [87] => WP_Term Object
                (
                    [term_id] => 87
                    [name] => Ownership of IP
                    [slug] => ownership-ip
                    [term_group] => 0
                    [term_taxonomy_id] => 87
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 87
                    [filter] => raw
                    [parent_name] => Intellectual property
                    [parent_slug] => ip-ownership
                )

            [70] => WP_Term Object
                (
                    [term_id] => 70
                    [name] => Payment structures
                    [slug] => royalties-and-payments
                    [term_group] => 0
                    [term_taxonomy_id] => 70
                    [taxonomy] => issue
                    [description] => What is the payment structure under this agreement? 
What are the mechanisms to limit exposure to additional payments or expenses?
                    [parent] => 53
                    [count] => 98
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [102] => WP_Term Object
                (
                    [term_id] => 102
                    [name] => Preparedness & response
                    [slug] => outbreak-preparedness
                    [term_group] => 0
                    [term_taxonomy_id] => 102
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 16
                    [filter] => raw
                    [parent_name] => Equitable access
                    [parent_slug] => access-to-medicines
                )

            [268] => WP_Term Object
                (
                    [term_id] => 268
                    [name] => Product supply
                    [slug] => supply-purchase-of-products
                    [term_group] => 0
                    [term_taxonomy_id] => 268
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 47
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [49] => WP_Term Object
                (
                    [term_id] => 49
                    [name] => Protecting & sharing information
                    [slug] => information-sharing
                    [term_group] => 0
                    [term_taxonomy_id] => 49
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [90] => WP_Term Object
                (
                    [term_id] => 90
                    [name] => Protection of IP
                    [slug] => protection-results
                    [term_group] => 0
                    [term_taxonomy_id] => 90
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 91
                    [filter] => raw
                    [parent_name] => Intellectual property
                    [parent_slug] => ip-ownership
                )

            [290] => WP_Term Object
                (
                    [term_id] => 290
                    [name] => Publication of results
                    [slug] => publication-of-results
                    [term_group] => 0
                    [term_taxonomy_id] => 290
                    [taxonomy] => issue
                    [description] => What information are the parties required or permitted to publish?
What is the required timeline for making data available?
What are the acceptable publication channels?
Is compliance with a specific open access policy required?
                    [parent] => 49
                    [count] => 72
                    [filter] => raw
                    [parent_name] => Protecting & sharing information
                    [parent_slug] => information-sharing
                )

            [372] => WP_Term Object
                (
                    [term_id] => 372
                    [name] => Quality management
                    [slug] => quality-management
                    [term_group] => 0
                    [term_taxonomy_id] => 372
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 47
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [56] => WP_Term Object
                (
                    [term_id] => 56
                    [name] => Regulatory strategy
                    [slug] => regulatory-strategy
                    [term_group] => 0
                    [term_taxonomy_id] => 56
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 62
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [81] => WP_Term Object
                (
                    [term_id] => 81
                    [name] => Representations & warranties
                    [slug] => warranties
                    [term_group] => 0
                    [term_taxonomy_id] => 81
                    [taxonomy] => issue
                    [description] => Should the parties make any warranties, and if so, what is the scope?
                    [parent] => 50
                    [count] => 108
                    [filter] => raw
                    [parent_name] => Liability
                    [parent_slug] => liability
                )

            [86] => WP_Term Object
                (
                    [term_id] => 86
                    [name] => Technology transfer
                    [slug] => technology-transfer
                    [term_group] => 0
                    [term_taxonomy_id] => 86
                    [taxonomy] => issue
                    [description] => What is included in the technology and/or materials to be transferred?
What are the responsibilities of each party to in relation to the transfer of materials and/or technology?
                    [parent] => 49
                    [count] => 49
                    [filter] => raw
                    [parent_name] => Protecting & sharing information
                    [parent_slug] => information-sharing
                )

            [52] => WP_Term Object
                (
                    [term_id] => 52
                    [name] => Term & termination
                    [slug] => term-and-termination
                    [term_group] => 0
                    [term_taxonomy_id] => 52
                    [taxonomy] => issue
                    [description] => Term

 	What is the term of the agreement? Is it tied to the timeline of the project or license grants?

Termination

 	Under what circumstances may a party terminate or withdraw from the agreement?

Effects of Termination

 	What are the effects of termination or withdrawal by a party?

                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [76] => WP_Term Object
                (
                    [term_id] => 76
                    [name] => Term of agreement
                    [slug] => term-of-agreement
                    [term_group] => 0
                    [term_taxonomy_id] => 76
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 52
                    [count] => 107
                    [filter] => raw
                    [parent_name] => Term & termination
                    [parent_slug] => term-and-termination
                )

            [74] => WP_Term Object
                (
                    [term_id] => 74
                    [name] => Termination & withdrawal
                    [slug] => termination-and-withdrawal
                    [term_group] => 0
                    [term_taxonomy_id] => 74
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 52
                    [count] => 112
                    [filter] => raw
                    [parent_name] => Term & termination
                    [parent_slug] => term-and-termination
                )

            [282] => WP_Term Object
                (
                    [term_id] => 282
                    [name] => Territory access commitments
                    [slug] => territory-access-commitments
                    [term_group] => 0
                    [term_taxonomy_id] => 282
                    [taxonomy] => issue
                    [description] => 
 	How should ‘territory’ be defined under the agreement? Should the definition make a distinction between different types of purchaser (e.g. public sector vs. private sector)?
 	Should the developer be required to apply for regulatory approval in priority access markets?
 	Should the developer be required to commit a proportion of the product manufactured to a certain country or purchasing organization?
 	Should the developer be required to identify a third party that could fulfill supply requirements for the access territories in the event that the developer does not?
 	Should the agreement include any anti-diversion provisions?

                    [parent] => 46
                    [count] => 69
                    [filter] => raw
                    [parent_name] => Equitable access
                    [parent_slug] => access-to-medicines
                )

        )

    [issues_by_slug:GHIAA2019\MapguideSearch:private] => Array
        (
            [equitable-access] => WP_Term Object
                (
                    [term_id] => 101
                    [name] => Access plans & principles
                    [slug] => equitable-access
                    [term_group] => 0
                    [term_taxonomy_id] => 101
                    [taxonomy] => issue
                    [description] => 
 	How should equitable or global access be defined?
 	Should the developer be required to comply with an equitable access policy?
 	Should the developer be required to establish an access plan?

                    [parent] => 46
                    [count] => 64
                    [filter] => raw
                    [parent_name] => Equitable access
                    [parent_slug] => access-to-medicines
                )

            [pricing] => WP_Term Object
                (
                    [term_id] => 100
                    [name] => Affordable pricing
                    [slug] => pricing
                    [term_group] => 0
                    [term_taxonomy_id] => 100
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 57
                    [filter] => raw
                    [parent_name] => Equitable access
                    [parent_slug] => access-to-medicines
                )

            [benefit-revenue-sharing] => WP_Term Object
                (
                    [term_id] => 66
                    [name] => Benefit sharing
                    [slug] => benefit-revenue-sharing
                    [term_group] => 0
                    [term_taxonomy_id] => 66
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 19
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [business-model] => WP_Term Object
                (
                    [term_id] => 53
                    [name] => Business model
                    [slug] => business-model
                    [term_group] => 0
                    [term_taxonomy_id] => 53
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [clinical-trial-conduct] => WP_Term Object
                (
                    [term_id] => 371
                    [name] => Clinical trial conduct
                    [slug] => clinical-trial-conduct
                    [term_group] => 0
                    [term_taxonomy_id] => 371
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 16
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [confidentiality] => WP_Term Object
                (
                    [term_id] => 84
                    [name] => Confidentiality
                    [slug] => confidentiality
                    [term_group] => 0
                    [term_taxonomy_id] => 84
                    [taxonomy] => issue
                    [description] => 
 	What is the scope of confidential information?
 	What are the obligations of the parties to protect confidential information?
 	Are there any exceptions to the confidentiality obligations?
 	Are the parties permitted to make public announcements related to the project?
 	Can the parties use each other’s name and logo for general marketing materials?

                    [parent] => 49
                    [count] => 123
                    [filter] => raw
                    [parent_name] => Protecting & sharing information
                    [parent_slug] => information-sharing
                )

            [donation] => WP_Term Object
                (
                    [term_id] => 271
                    [name] => Donation
                    [slug] => donation
                    [term_group] => 0
                    [term_taxonomy_id] => 271
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 5
                    [filter] => raw
                    [parent_name] => Equitable access
                    [parent_slug] => access-to-medicines
                )

            [effect-of-termination] => WP_Term Object
                (
                    [term_id] => 72
                    [name] => Effects of termination
                    [slug] => effect-of-termination
                    [term_group] => 0
                    [term_taxonomy_id] => 72
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 52
                    [count] => 106
                    [filter] => raw
                    [parent_name] => Term & termination
                    [parent_slug] => term-and-termination
                )

            [ensuring-continuity] => WP_Term Object
                (
                    [term_id] => 281
                    [name] => Ensuring continuity
                    [slug] => ensuring-continuity
                    [term_group] => 0
                    [term_taxonomy_id] => 281
                    [taxonomy] => issue
                    [description] => 
 	Under what circumstances can the continuity rights be exercised? (What are the conditions precedent?)
 	What is an appropriate scope for the continuity rights? What are the rights and obligations of each party?
 	Should related license grants vest upon execution of the agreement, or at a later stage in development?
 	Should there be an escrow requirement?
 	Should there be any restrictions on the developer’s ability to transfer project-related intellectual property to a third party?

                    [parent] => 46
                    [count] => 64
                    [filter] => raw
                    [parent_name] => Equitable access
                    [parent_slug] => access-to-medicines
                )

            [access-to-medicines] => WP_Term Object
                (
                    [term_id] => 46
                    [name] => Equitable access
                    [slug] => access-to-medicines
                    [term_group] => 0
                    [term_taxonomy_id] => 46
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [roles-responsibilities] => WP_Term Object
                (
                    [term_id] => 278
                    [name] => Governance
                    [slug] => roles-responsibilities
                    [term_group] => 0
                    [term_taxonomy_id] => 278
                    [taxonomy] => issue
                    [description] => 
 	Do the parties govern the project through a joint steering committee ("JSC")? If so, what are the parties expressly designated roles and responsibilities with respect to the JSC?
 	Are there other committees, important governance bodies, or designated individual positions? What are the parties' roles and responsibilities with respect to them?
 	Are the parties required to meet in accordance with a defined schedule for decision-making and progress reporting activities?
 	What are the resolution mechanisms for disputes related to the agreement?
 	Are there any requirements for policies or procedures to manage potential conflicts of interest?

                    [parent] => 53
                    [count] => 109
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [indemnity] => WP_Term Object
                (
                    [term_id] => 80
                    [name] => Indemnification & liability
                    [slug] => indemnity
                    [term_group] => 0
                    [term_taxonomy_id] => 80
                    [taxonomy] => issue
                    [description] => 
 	What occurrences could result in a liability claim against which one party will indemnify the other?
 	Are there any circumstances under which one party will not indemnify the other?
 	What is the process for managing liability claims?
 	Are there government or other types of indemnification schemes?
 	Is there any limitation or monetary cap on each party’s liabilities under the agreement?

                    [parent] => 50
                    [count] => 120
                    [filter] => raw
                    [parent_name] => Liability
                    [parent_slug] => liability
                )

            [information-sharing-information-sharing] => WP_Term Object
                (
                    [term_id] => 257
                    [name] => Information sharing
                    [slug] => information-sharing-information-sharing
                    [term_group] => 0
                    [term_taxonomy_id] => 257
                    [taxonomy] => issue
                    [description] => 
 	What financial and project progress information must be shared between the parties?
 	What is the required timeline for sharing information?
 	How is the receiving party permitted to use the information received?
 	Do the parties have the right to verify the information reported?

                    [parent] => 49
                    [count] => 114
                    [filter] => raw
                    [parent_name] => Protecting & sharing information
                    [parent_slug] => information-sharing
                )

            [insurance] => WP_Term Object
                (
                    [term_id] => 109
                    [name] => Insurance
                    [slug] => insurance
                    [term_group] => 0
                    [term_taxonomy_id] => 109
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 50
                    [count] => 76
                    [filter] => raw
                    [parent_name] => Liability
                    [parent_slug] => liability
                )

            [ip-ownership] => WP_Term Object
                (
                    [term_id] => 48
                    [name] => Intellectual property
                    [slug] => ip-ownership
                    [term_group] => 0
                    [term_taxonomy_id] => 48
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [liability] => WP_Term Object
                (
                    [term_id] => 50
                    [name] => Liability
                    [slug] => liability
                    [term_group] => 0
                    [term_taxonomy_id] => 50
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [license-grants] => WP_Term Object
                (
                    [term_id] => 88
                    [name] => License grants
                    [slug] => license-grants
                    [term_group] => 0
                    [term_taxonomy_id] => 88
                    [taxonomy] => issue
                    [description] => 
 	Are any licenses granted for the use of background or foreground intellectual property?
 	What is the scope of the licensed intellectual property?
 	What is the territory of the license?
 	Is the license exclusive or non-exclusive?
 	Are there any restrictions on the use of the licensed intellectual property?
 	Are there any specific obligations to exploit the licensed intellectual property?
 	Can the licensee grant sublicenses to third parties?
 	Will products manufactured under license be marketed as branded or generic? (i.e. will they bear the licensor’s trademarks/trade dress)

                    [parent] => 48
                    [count] => 115
                    [filter] => raw
                    [parent_name] => Intellectual property
                    [parent_slug] => ip-ownership
                )

            [ownership-ip] => WP_Term Object
                (
                    [term_id] => 87
                    [name] => Ownership of IP
                    [slug] => ownership-ip
                    [term_group] => 0
                    [term_taxonomy_id] => 87
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 87
                    [filter] => raw
                    [parent_name] => Intellectual property
                    [parent_slug] => ip-ownership
                )

            [royalties-and-payments] => WP_Term Object
                (
                    [term_id] => 70
                    [name] => Payment structures
                    [slug] => royalties-and-payments
                    [term_group] => 0
                    [term_taxonomy_id] => 70
                    [taxonomy] => issue
                    [description] => What is the payment structure under this agreement? 
What are the mechanisms to limit exposure to additional payments or expenses?
                    [parent] => 53
                    [count] => 98
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [outbreak-preparedness] => WP_Term Object
                (
                    [term_id] => 102
                    [name] => Preparedness & response
                    [slug] => outbreak-preparedness
                    [term_group] => 0
                    [term_taxonomy_id] => 102
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 16
                    [filter] => raw
                    [parent_name] => Equitable access
                    [parent_slug] => access-to-medicines
                )

            [supply-purchase-of-products] => WP_Term Object
                (
                    [term_id] => 268
                    [name] => Product supply
                    [slug] => supply-purchase-of-products
                    [term_group] => 0
                    [term_taxonomy_id] => 268
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 47
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [information-sharing] => WP_Term Object
                (
                    [term_id] => 49
                    [name] => Protecting & sharing information
                    [slug] => information-sharing
                    [term_group] => 0
                    [term_taxonomy_id] => 49
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [protection-results] => WP_Term Object
                (
                    [term_id] => 90
                    [name] => Protection of IP
                    [slug] => protection-results
                    [term_group] => 0
                    [term_taxonomy_id] => 90
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 91
                    [filter] => raw
                    [parent_name] => Intellectual property
                    [parent_slug] => ip-ownership
                )

            [publication-of-results] => WP_Term Object
                (
                    [term_id] => 290
                    [name] => Publication of results
                    [slug] => publication-of-results
                    [term_group] => 0
                    [term_taxonomy_id] => 290
                    [taxonomy] => issue
                    [description] => What information are the parties required or permitted to publish?
What is the required timeline for making data available?
What are the acceptable publication channels?
Is compliance with a specific open access policy required?
                    [parent] => 49
                    [count] => 72
                    [filter] => raw
                    [parent_name] => Protecting & sharing information
                    [parent_slug] => information-sharing
                )

            [quality-management] => WP_Term Object
                (
                    [term_id] => 372
                    [name] => Quality management
                    [slug] => quality-management
                    [term_group] => 0
                    [term_taxonomy_id] => 372
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 47
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [regulatory-strategy] => WP_Term Object
                (
                    [term_id] => 56
                    [name] => Regulatory strategy
                    [slug] => regulatory-strategy
                    [term_group] => 0
                    [term_taxonomy_id] => 56
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 62
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [warranties] => WP_Term Object
                (
                    [term_id] => 81
                    [name] => Representations & warranties
                    [slug] => warranties
                    [term_group] => 0
                    [term_taxonomy_id] => 81
                    [taxonomy] => issue
                    [description] => Should the parties make any warranties, and if so, what is the scope?
                    [parent] => 50
                    [count] => 108
                    [filter] => raw
                    [parent_name] => Liability
                    [parent_slug] => liability
                )

            [technology-transfer] => WP_Term Object
                (
                    [term_id] => 86
                    [name] => Technology transfer
                    [slug] => technology-transfer
                    [term_group] => 0
                    [term_taxonomy_id] => 86
                    [taxonomy] => issue
                    [description] => What is included in the technology and/or materials to be transferred?
What are the responsibilities of each party to in relation to the transfer of materials and/or technology?
                    [parent] => 49
                    [count] => 49
                    [filter] => raw
                    [parent_name] => Protecting & sharing information
                    [parent_slug] => information-sharing
                )

            [term-and-termination] => WP_Term Object
                (
                    [term_id] => 52
                    [name] => Term & termination
                    [slug] => term-and-termination
                    [term_group] => 0
                    [term_taxonomy_id] => 52
                    [taxonomy] => issue
                    [description] => Term

 	What is the term of the agreement? Is it tied to the timeline of the project or license grants?

Termination

 	Under what circumstances may a party terminate or withdraw from the agreement?

Effects of Termination

 	What are the effects of termination or withdrawal by a party?

                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [term-of-agreement] => WP_Term Object
                (
                    [term_id] => 76
                    [name] => Term of agreement
                    [slug] => term-of-agreement
                    [term_group] => 0
                    [term_taxonomy_id] => 76
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 52
                    [count] => 107
                    [filter] => raw
                    [parent_name] => Term & termination
                    [parent_slug] => term-and-termination
                )

            [termination-and-withdrawal] => WP_Term Object
                (
                    [term_id] => 74
                    [name] => Termination & withdrawal
                    [slug] => termination-and-withdrawal
                    [term_group] => 0
                    [term_taxonomy_id] => 74
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 52
                    [count] => 112
                    [filter] => raw
                    [parent_name] => Term & termination
                    [parent_slug] => term-and-termination
                )

            [territory-access-commitments] => WP_Term Object
                (
                    [term_id] => 282
                    [name] => Territory access commitments
                    [slug] => territory-access-commitments
                    [term_group] => 0
                    [term_taxonomy_id] => 282
                    [taxonomy] => issue
                    [description] => 
 	How should ‘territory’ be defined under the agreement? Should the definition make a distinction between different types of purchaser (e.g. public sector vs. private sector)?
 	Should the developer be required to apply for regulatory approval in priority access markets?
 	Should the developer be required to commit a proportion of the product manufactured to a certain country or purchasing organization?
 	Should the developer be required to identify a third party that could fulfill supply requirements for the access territories in the event that the developer does not?
 	Should the agreement include any anti-diversion provisions?

                    [parent] => 46
                    [count] => 69
                    [filter] => raw
                    [parent_name] => Equitable access
                    [parent_slug] => access-to-medicines
                )

        )

    [filter_issues:GHIAA2019\MapguideSearch:private] => Array
        (
        )

)